Oct. 30, 2009 (China Knowledge) - Anhui Anke Biotechnology (Group) Co Ltd<300009>, a bio-pharmaceutical maker, debuted on the ChiNext Board on the Shenzhen Stock Exchange today, becoming one of the first companies to trade on the Nasdaq-style board.

Shares of the company opened at RMB 37, a price 117.65% higher than the IPO price, while the Shenzhen Component Index opened 1.92% higher at 12427.10 points.

The company raised RMB 166 million by issuing 21 million shares, or 25% of the company’s enlarged capital. Sinolink Securities Co Ltd<600109> was the underwriter of the offering.

Anhui Anke Biotechnology, which specializes in developing, manufacturing and marketing pharmaceuticals and health-care products, posted RMB 143.92 million of operating revenue in the third quarter of this year, with net profit hitting RMB 35.87 million during the period.